Skip directly to content

In the end it’s all about sex & death. But in the America in which AIDS emerged, a medieval plague in a modern time, sex & death were the two enduring taboos, especially when the sex was homosex, & the deaths were coming unnaturally young & ugly & in growing numbers. So in the beginning we had just ourselves. Gay guys, to whom this devastation was mostly happening, repurposed our sexual & social networks to create the first AIDS service organizations when government at every level said in effect: drop dead.

Webinar: Envisioning comprehensive HIV prevention service delivery in the U.S.

RELATED: Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan


December 18, 2015

A collaboration between Treatment Action Group and the HIV Prevention Justice Alliance, this webinar discusses the current state of the HIV prevention toolbox and introduced the HIV prevention continuum.

Moderated by TAG's Jeremiah Johnson, with panelists K. Rivet Amico, Dazon Dixon Diallo, and Jim Pickett.

Stayed tuned for another TAG and HIV PJA collaborative webinar announcement soon!

2015 TAGupdate


December 2015

In this issue:

  • Letter from Kenyon Farrow, TAG's U.S. & Global Health Policy Director
  • Message from Board President Barbara Hughes
  • Ending the Epidemic Update
  • HCV Report from the Front


December 8, 2015

DOWNLOAD: HCV Webinar #1: The Cost of Production for HCV Treatment Slides

Presenter: Dr. Andrew Hill, Senior Research Fellow, Department of Pharmacology and Therapeutics, Liverpool University, United Kingdom

Description: New HCV drugs, called direct-acting antivirals (DAAs), are too expensive. Generic DAAs will be key to provide universal access to treatment for millions of people with hepatitis C, espcially in low- and middle-income countries (LMICs). In this webinar, Dr.


The goal of hepatitis C virus (HCV) treatment is a cure (when there is no hepatitis C virus in a person’s bloodstream at least 12 weeks after treatment is finished).

What is ribavirin?

Ribavirin (RBV) is an HCV-fighting drug. RBV does not work by itself. Adding RBV to other drugs can increase the chance of being cured from HCV. In the United States, ribavirin is approved for children (3 to 18 years of age) and adults.

RBV is made by Merck (sold as Rebetol), Genentech (sold as Copegus), and Kadmon Pharmaceuticals (sold as Ribasphere).

How is

Viekira XR and Technivie Fact Sheet

Updated February 2017

The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished).

What is Viekira XR?

Viekira XR is a combination of hepatitis C virus–fighting drugs (paritaprevir/ritonavir/ombitasvir and dasabuvir) that block different steps of the virus life cycle. In the United States, Viekira XR is approved for people with hepatitis C genotype 1 who are over 18 years old.

Hepatitis C Virus (HCV) Diagnostics Fact Sheet

What is screening?

Screening looks to see whether someone might have a disease. For hepatitis C virus (HCV), screening means looking for antibodies instead of the virus.

What are antibodies?

Antibodies are Y-shaped proteins made by a person’s immune system. They are part of the immune system’s response to viruses, bacteria, and other harmful substances (called antigens).

Antibodies attach themselves to antigens or infected cells and tag them so that other immune cells can find and disable them.

Adherence Fact Sheet

What is adherence?

Adherence means sticking to something. It is often used to describe taking medicine without missing doses for as long as needed. Good adherence helps to maintain—or improve—your health.

This fact sheet is about adherence to hepatitis C treatment. It may be helpful for other medications, whether you are taking them for a short time, or for the rest of your life.

With hepatitis C treatment, the most important thing a person can do to be cured is not to miss taking any of their medication—and to finish all of it.